![]() |
Home
Search
Study Topics
Glossary
|
Study 7 of 470 for search of: | "Schering-Plough" [Exact] |
![]() |
Previous Study | Return to Search Results | Next Study |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Schering-Plough |
---|---|
Information provided by: | Schering-Plough |
ClinicalTrials.gov Identifier: | NCT00632502 |
4-Week Safety Study in Subjects with Neutrophilic Asthma
Condition | Intervention | Phase |
---|---|---|
Neutrophilic Asthma |
Drug: SCH 527123 Drug: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety Study |
Official Title: | Safety of SCH 527123 in Subjects With Neutrophilic Asthma |
Estimated Enrollment: | 30 |
Study Start Date: | May 2008 |
Estimated Study Completion Date: | February 2009 |
Estimated Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
SCH 527123: Experimental
30 mg capsule, to be taken once daily in the morning
|
Drug: SCH 527123
30 mg capsule to be taken once daily in the morning for 4 weeks.
|
Placebo: Placebo Comparator
Placebo capsule to match SCH 527123, to be taken once daily in the morning
|
Drug: Placebo
Placebo capsule to match SCH 527123 to be taken once daily in the morning for 4 weeks.
|
Effect of treatment with SCH 527123 on sputum neutrophils and asthma symptoms. Pharmacokinetics of SCH 527123.
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: SP Clinical Trial Registry Call Center | 1-888-772-8734 |
Canada | |
Investigational Site 12 | Recruiting |
Hamilton, Canada, L8N 4A6 | |
Investigational Site 25 | Recruiting |
Hamilton, Canada, L8N 3Z5 | |
France | |
Investigational Site 14 | Recruiting |
Montpellier Cedex 5, France, 34295 | |
Investigational Site 13 | Recruiting |
Marseille Cedex 9, France, 13274 | |
Germany | |
Investigational Site 18 | Recruiting |
Hamburg, Germany, 22291 | |
Greece | |
Investigational Site 11 | Recruiting |
Athens, Greece, GR 11527 | |
Italy | |
Investigational Site 17 | Recruiting |
Palermo, Italy, 90146 | |
Investigational Site 16 | Recruiting |
Foggia, Italy, 71100 |
Responsible Party: | Schering-Plough ( Head, Clinical Trials Registry & Results Disclosure Group ) |
Study ID Numbers: | P05365, Doc ID: 3709483 |
Study First Received: | February 29, 2008 |
Last Updated: | January 28, 2009 |
ClinicalTrials.gov Identifier: | NCT00632502 |
Health Authority: | Greece: National Drug Authority |
Hypersensitivity Lung Diseases, Obstructive Respiratory Tract Diseases Bronchial Diseases |
Lung Diseases Hypersensitivity, Immediate Asthma Respiratory Hypersensitivity |
Immune System Diseases |